Sustained Efficacy and Safety in C3 Glomerulopathy Following 36 Months of Oral Treatment with Iptacopan: Interim Participant Results from the APPEAR-C3G Extension Study (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-OR078; Pres time: Oct 24, 2026; 05:30 PM - 05:42 PM; Location: Four Seasons Ballroom 2; P3 | "This analysis confirms previous findings demonstrating sustained efficacy and safety of oral iptacopan over 3 years. To date, this is the largest cohort with long-term follow up data in participants with C3G receiving iptacopan in clinical trials, addressing a gap that may inform clinical practice in this population."
Clinical • Late-breaking abstract • Complement-mediated Rare Disorders • Glomerulonephritis • Infectious Disease • Meningococcal Infections
|
|
Carla M. Nester1; Raquel Luna Yolba9; Severina Jacinto-Sanders9; Jean Grisouard9; Andrew S. Bomback10; Richard J. Smith2; David Kavanagh3,4; Marina Vivarelli5; Giuseppe Remuzzi6; Minghui Zhao7; Edwin Kwan Soon Wong3; Shiwei Cao8; Rubeen K. Israni8
|